Full Text Journal Articles from
Abstract 32250749


Find full text journal articles

Chronic migraine and Botulinum Toxin Type A: Where do paths cross?

PMID: 32250749 (view PubMed database entry)
DOI: 10.1016/j.toxicon.2020.02.017 (read at publisher's website )

Daniele Martinelli, Sebastiano Arceri, Livio Tronconi, Cristina Tassorelli,

Migraine is a highly prevalent and disabling disorder accounted among the primary headaches. It is the expression of a complex, and not yet fully understood, pathophysiology involving the sensitization of peripheral and central nociceptive pathways. In this review we succinctly illustrate the molecular, anatomical, and functional abnormalities underlying the migraine attack that are relevant for understanding in more depth the neurobiology behind the therapeutic effect of Botulinum Toxin Type A (BoNT-A). BoNT-A has proved effective in several neurological conditions and, more recently, also in chronic migraine. Its antimigraine mechanism of action was initially thought to be limited to the periphery and interpreted as an inhibitory activity on the processes associated to the local release of neuropeptides, with subsequent induction of peripheral sensitization. Increasing experimental evidence has become available to suggest that additional mechanisms are possibly involved, including the direct/indirect inhibition of sensitization processes in central nociceptive pathways.

Toxicon (Toxicon : official journal of the International Society on Toxinology)
[2020, 178:69-76]

Cited: 0 times

AltMetric Statistics

Additional resources:


0.3997 s